Company says it will seek approval of Alzheimer’s drug

News
prescription drugs_267709

BOSTON, Mass. (AP)–The drug company Biogen Inc. says it will seek federal approval for a medicine to treat early Alzheimer’s disease, a landmark step toward finding a treatment that can alter the course of the most common form of dementia.

The announcement is a surprise because the company earlier this year stopped two studies of the drug when partial results suggested it was not working. The company now says a new analysis of more results suggest that the drug helped reduce a decline of thinking skills at the highest dose.

The drug, called aducanumab, aims to help the body clear harmful plaques from the brain. Cambridge, Massachusetts-based Biogen is developing it with a Japanese company, Eisai Co. Ltd. Shares of Biogen soared 36% to $305 in pre-market trading Tuesday.

Copyright 2019 Nexstar Broadcasting, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

State Police Overtime Scandal

More State Police Overtime Investigation

Trending Stories